XML 33 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Note 8 - Other Intangible Assets
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]

NOTE 8. OTHER INTANGIBLE ASSETS

 

The following roll-forward presents the Company’s other intangible assets as of December 31, 2023 (in thousands):

 

   

Balance at December 31, 2023

  
           

Accumulated

    

Impairments

         
   

Gross

    

Amortization

    

to Date

    

Net

  

Indefinite-lived intangible assets

                                

DERMAdoctor Trade names

   $ 2,080     $ —     $ (2,080 )   $ —  
                                 

Amortizable intangible assets

                                

DERMAdoctor Customer relationships

     290       (60 )     (230 )     —  

DERMAdoctor Trade secrets / product formulations

     2,890       (515 )     (2,375 )     —  
                                 

Total other intangible assets

   $ 5,260     $ (575 )   $ (4,685 )   $ —  

 

The Company determined that its indefinite-lived and long-lived amortizable intangible assets related to its DERMAdoctor business were fully impaired during the year ended December 31, 2023. As such, the Company recorded an intangible asset impairment charge of $2.1 million in the year ended December 31, 2023 which is included in net loss from discontinued operations in the Company’s consolidated statements of operations. There was no such intangible asset impairment charge recorded during the year ended December 31, 2024. The impairment information is discussed in Note 2, “Summary of Significant Accounting Policies.” On March 25, 2024, we closed the DERMAdoctor Divestiture, resulting in the sale of the indefinite-lived and long-lived amortizable intangible assets. See additional information in Note 21, “DERMAdoctor Divestiture and Discontinued Operations.”

 

Amortization expense was $152 thousand during the year ended December 31, 2023 which is included in net loss from discontinued operations. There was no such expense recorded during the year ended December 31, 2024 as the related assets were fully impaired prior to 2024 and subsequently sold in conjunction with the DERMAdoctor Divestiture.